{
  "created_at": "Wed Aug 11 11:44:13 +0000 2021",
  "id_str": "1425269429261189120",
  "full_text": "Shares of Moderna have soared so much that the biotechnology company’s valuation is “unjustifiable on a fundamental basis,” said one analyst. https://t.co/TCcUV0x5QC",
  "display_text_range": [
    0,
    165
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/TCcUV0x5QC",
        "expanded_url": "https://on.mktw.net/3lSk2OG",
        "display_url": "on.mktw.net/3lSk2OG",
        "indices": [
          142,
          165
        ]
      }
    ]
  },
  "user": {
    "name": "MarketWatch",
    "screen_name": "MarketWatch",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/705601245596090368/Z6xUOnRg_normal.jpg"
  },
  "retweet_count": 79,
  "favorite_count": 179,
  "possibly_sensitive": false,
  "original_created_at": "Wed Aug 11 01:34:46 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "あるアナリストは、Moderna社の株価があまりにも高騰しているため、このバイオテクノロジー企業の評価は「ファンダメンタルベースで正当化できない」と述べている。https://t.co/TCcUV0x5QC。"
    },
    {
      "locale": "zh",
      "full_text": "Moderna的股价已经飙升，以至于这家生物技术公司的估值 \"在基本面上是不合理的\"，一位分析师说。https://t.co/TCcUV0x5QC。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "Moderna的股價已經飆升，以至於這家生物技術公司的估值 \"在基本面上是不合理的\"，一位分析師說。https://t.co/TCcUV0x5QC。"
    }
  ],
  "source_updated_at": 1628847703275
}